BRCA1 and cancer: For example, cancer cells deficient in BRCA1 tend to exhibit defective DNA repair, and in turn, are sensitive to drugs such as mitomycin C and cisplatin, which induce intrastrand and interstrand DNA crosslinks, stalled replication forks, and DNA double-strand breaks [15-20], and PARP inhibitors, which through a synthetic lethal mechanism further inhibit DNA repair mechanisms and promote cytotoxicity [21,22].